Immune Suppression Of Infants Treated With Steroids

Status Completed

Clinical Trial Summary

The goal of this study is to clarify the degree of immune suppression in infants requiring therapy and to create guidelines for evaluation and prevention of infection in infants on oral steroids for hemangiomas.

Clinical Trial Description

Infants with large or complicated hemangiomas are often treated systemically with oral steroids. The side effects of the drug on young infants has not been studied. The goal of this study is to clarify the degree of immune suppression in infants requiring therapy and to create guidelines for evaluation and prevention of infection in infants on oral steroids for hemangiomas. Prednisone will be started according to established standard of care. Visits will occur every four weeks for follow-up. There will be six blood draws from baseline to completion of study. Approximately up to 1 ½ teaspoons per blood sample will be drawn to test the strength of the infant's immune system. Participation in this study will last up to 14 months or until stabilization of the hemangioma. Evaluation will occur 12 weeks after discontinuing the steroid for its long-term effects on the immune system. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Hemangioma

Clinical Trial Details

NCT number	NCT00433940
Study type	Observational
Source	Medical College of Wisconsin
Contact
Status	Completed
Phase	N/A
Start date	October 2006
Completion date	July 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01685398` - Topical Timolol for Superficial Infantile Hemangioma	Phase 3
Withdrawn	`NCT00974129` - A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas	N/A
Completed	`NCT00374335` - Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas	N/A
Recruiting	`NCT03331744` - Clinical Characteristics of Infantile Hemangioma
Completed	`NCT02342275` - Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma	Phase 3
Completed	`NCT04065217` - The Effectiveness of Diode Laser 980-nm in Iraqi Face Hemangioma: a Randomized Within Patients Trial	N/A
Terminated	`NCT01743885` - Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma	Phase 3
Terminated	`NCT00555464` - Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas	Phase 2
Completed	`NCT00394888` - Hemangioma Associated With High Rates of Morbidity	N/A
Completed	`NCT05327309` - Role of Propranolol as Compared to Bleomycin in Management of Hemangioma	N/A
Completed	`NCT02145884` - Topical Timolol Gel for the Treatment of Infantile Hemangiomas	Phase 2
Completed	`NCT04077515` - Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma	Phase 4
Completed	`NCT02731287` - Topical Timolol for Infantile Hemangioma in Early Proliferative Phase	Phase 2
Recruiting	`NCT01147601` - Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas	Phase 0
Completed	`NCT01908972` - The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma	Phase 4
Completed	`NCT00540566` - Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Completed	`NCT00001417` - Direct Injection of Alcohol for the Treatment of Spinal Tumors	N/A
Completed	`NCT00004436` - Randomized Study of Hormonal Regulation of Infantile Hemangioma	N/A
Recruiting	`NCT02496013` - Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB	Phase 1
Completed	`NCT01072045` - Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma	Phase 2